Endothelin-1 (ET-1) and vein graft failure and the therapeutic potential of ET-1 receptor antagonists

Pharmacological Research

Volumn 63, Issue 6, 2011, Pages 483-489

  Jeremy, Jamie Y ^a   Shukla, Nilima ^a   Angelini, Gianni D ^a   Wan, Song ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Coronary artery bypass graft surgery; Endothelin 1; ET A receptor antagonist

Indexed keywords

BSF 302146; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; NITRIC OXIDE; UNCLASSIFIED DRUG;

ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CELL PROLIFERATION; CORONARY ARTERY BYPASS GRAFT; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG MECHANISM; EARLY INTERVENTION; HEADACHE; HEART MUSCLE ISCHEMIA; HUMAN; HYPOXIA; NONHUMAN; NOSE CONGESTION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPERFUSION INJURY; REVIEW; RISK FACTOR; THROMBOSIS; UPREGULATION; VASA VASORUM; VASOCONSTRICTION; VEIN GRAFT DISEASE;

ENDOTHELIN-1; GRAFT OCCLUSION, VASCULAR; GRAFT REJECTION; HUMANS; MOLECULAR TARGETED THERAPY; NEOINTIMA; RECEPTOR, ENDOTHELIN A; VEINS;

EID: 79958036103     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2010.10.018     Document Type: Review

References (98)

1. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease. Pathogenesis, predisposition and prevention. Circulation 1998;97:916-31.
2. Jeremy JY, Gadsdon P, Shukla N, Vijayan V, Wyatt M, Newby AC, et al. On the biology of saphenous vein grafts fitted with external synthetic sheaths and stents. Biomaterials 2007;28:895-908. (Pubitemid 44809429)
3. Campeau L. Lipid lowering and coronary bypass graft surgery. Curr Opin Cardiol 2000;15:395-9.
4. Kulik A, Ruel M. Statins and coronary artery bypass graft surgery: preoperative and postoperative efficacy and safety. Expert Opin Drug Saf 2009;8:559-71.
5. Souza DS, Dashwood MR, Tsui JC, Filbey D, Bodin L, Johansson B, et al. Improved patency in vein grafts harvested with surrounding tissue: results of a randomized study using three harvesting techniques. Ann Thorac Surg 2002;73:1189-95. (Pubitemid 34275904)
6. Souza DS, Johansson B, Bojö L, Karlsson R, Geijer H, Filbey D, et al. Harvesting the saphenous vein with surrounding tissue for CABG provides long-term graft patency comparable to the left internal thoracic artery: results of a randomized longitudinal trial. J Thorac Cardiovasc Surg 2006;132:373-8.
7. Dashwood MR, Savage K, Tsui JC, Dooley A, Shaw SG, Fernández Alfonso MS, et al. Retaining perivascular tissue of human saphenous vein grafts protects against surgical and distension-induced damage and preserves endothelial nitric oxide synthase and nitric oxide synthase activity. J Thorac Cardiovasc Surg 2009;138:334-40.
8. Dashwood MR, Dooley A, Shi-Wen X, Abraham DJ, Souza DS. Does periadventitial fat-derived nitric oxide play a role in improved saphenous vein graft patency in patients undergoing coronary artery bypass surgery? J Vasc Res 2007;44:175-81.
9. Jeremy JY, Shukla N, Wan S, Yim A, Angelin GD, Murphy G, et al. Are ETA receptor antagonists the solution to preventing vein graft failure? Curr Vasc Pharmacol 2005;3:315-23.
10. Dashwood MR. Endothelin-1 and vein graft occlusion in patients undergoing bypass surgery. Eur J Clin Invest 2009;39:79-87.
11. Jeremy JY, Mehta D, Bryan AJ, Angelini GD. Platelets and saphenous vein graft failure. Platelets 1997;8:295-309.
12. Jeremy JY, Jackson CL, Bryan AJ, Angelini GD. Eicosanoids, fatty acids and restenosis following coronary artery bypass graft surgery and balloon angioplasty. Prostaglandins Leukot Essent Fatty Acids 1996;54:385-402. (Pubitemid 26313457)
13. Jeremy JY, Rowe D, Emsley AM, Newby AC. Nitric oxide and vascular smooth muscle cell proliferation. Cardiovasc Res 1999;43:580-94. (Pubitemid 29369257)
14. Khimji A, Rockey DC. Endothelin - biology and disease. Cell Signal 2010;22:1615-25.
15. Thorin E, Webb DJ. Endothelium-derived endothelin-1. Pflugers Arch 2010;459:951-8.
16. Malmstrom RE, Settergren M, Pernow J. Endothelin attenuates endothelium-dependent platelet inhibition in man. Acta Physiol 2010;198:441-8.
17. Yanagisawa M, Inoue A, Ishikawa T. Primary structure, synthesis, and biological activity of rat endothelin, an endothelium-derived vasoconstrictor peptide. Proc Natl Acad Sci U S A 1988;85:6964-7.
18. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994;46(September (3)):325-415.
19. Maguire JJ, Davenport AP. Endothelin receptor expression and pharmacology in human saphenous vein graft. Br J Pharmacol 1999;126:443-50. (Pubitemid 29057595)
20. Maguire JJ, Yu CM, Davenport AP. ETA receptor antagonists inhibit intimal smooth muscle cell proliferation in human vessels. Clin Sci 2002;103:184S-8S.
21. Dashwood MR, Jeremy JY, Mehta D, Izzat MB, Timm M, Bryan AJ, et al. Endothelin-1 and endothelin receptors in porcine saphenous vein-carotid artery grafts. J Cardiovasc Pharmacol 1998;31(Suppl. 1):S328-30.
22. B) receptor binding to different regions of porcine interposition venous-arterial grafts. Atherosclerosis 1998;137:233-42.
23. Dashwood MR, Anand R, Loesch A, Souza D. Surgical trauma and vein graft failure: further evidence for a role of ET-1 in graft occlusion. J Cardiovasc Pharmacol 2004;44(Suppl. 1):385-95.
24. Halcox JPJ, Nour KRA, Zalos G, Quyyumi AA. Endogenous endothelin in human coronary vascular function differential contribution of endothelin receptor types A and B. Hypertension 2007;49:1134-41. (Pubitemid 351664308)
25. Motte S, McEntee K, Naeije R. Endothelin receptor antagonists. Pharmacol Ther 2006;110:386-414.
26. Berti F, Rossoni G, Della Bella D, Villa LM, Buschi A, Trento F, et al. Nitric oxide and prostacyclin influence coronary vasomotor tone in perfused rabbit heart and modulate endothelin-1 activity. J Cardiovasc Pharmacol 1993;22:321-6. (Pubitemid 23225162)
27. Wenzel RR, Fleisch M, Shaw S, Noll G, Kaufmann U, Schmitt R, et al. Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. Circulation 1998;98:2235-40. (Pubitemid 28533840)
28. Swigris JJ, Brown KK. The role of endothelin-1 in the pathogenesis of idiopathic pulmonary fibrosis. BioDrugs 2010;24:49-54.
29. Sessa WC, Kaw S, Hecker M, Vane JR. The biosynthesis of endothelin-1 by human polymorphonuclear leukocytes. Biochem Biophys Res Commun 1991;174:613-8.
30. Gomez-Garre D, Guerra M, Gonzalez E, López-Farré A, Riesco A, Caramelo C, et al. Aggregation of human polymorphonuclear leukocytes by endothelin: role of platelet-activating factor. Eur J Pharmacol 1992;224:167-72.
31. Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 2005;85:1-31. (Pubitemid 40171256)
32. Jeremy JY, Thomas AC. Animal models for studying neointima formation. Curr Vasc Pharmacol 2010;8:198-219.
33. A receptor antagonist, BSF 302146, is a potent inhibitor of neointimal and medial thickening in porcine saphenous vein-carotid artery interposition grafts. J Thorac Cardiovasc Surg 2004;127:1317-22.
34. Kitada K, Yui N, Matsumoto C, Mori T, Ohkita M, Matsumura Y. Inhibition of endothelin ETB receptor system aggravates neointimal hyperplasia after balloon injury of rat carotid artery. J Pharmacol Exp Ther 2009;331:998-1004.
35. Jeremy JY, Shukla N, Muzaffar S, Angelini GD. Reactive oxygen species, vascular disease and cardiovascular surgery. Curr Vasc Pharmacol 2004;2:229-36. (Pubitemid 38855029)
36. Jeremy JY, Yim AP, Wan S, Angelini GD. Oxidative stress, nitric oxide and vascular disease. Cardiovasc Surg 2002;17:324-7. (Pubitemid 36071987)
37. West N, Guzik T, Black E, Channon K. Enhanced superoxide production in experimental venous bypass graft intimal hyperplasia: role of NAD(P)H oxidase. Arterioscler Thromb Vasc Biol 2001;21:189-94. (Pubitemid 32125364)
38. Bloor J, Shukla N, Smith FCT, Angelini GD, Jeremy JY. Folic acid administration reduces neointimal thickening, augments neo vasa vasorum formation and reduces oxidative stress in saphenous vein grafts from diabetic pigs. Diabetologia 2010;53:980-8.
39. Wan S, Yim A, Shukla N, Johnson JL, Angelini GD, Jeremy JY. Orally administered penicillamine is a potent inhibitor of neointimal and medial thickening in porcine saphenous vein grafts. J Thorac Cardiovasc Surg 2007;133:494-500. (Pubitemid 46136253)
40. Shi Y, Patel S, Davenpeck KL, Niculescu R, Rodriguez E, Magno MG, et al. Oxidative stress and lipid retention in vascular grafts: comparison between venous and arterial conduits. Circulation 2001;103:2408-13. (Pubitemid 32448808)
41. Huynh TT, Davies MG, Trovato MJ, Barber L, Safi HJ, Hagen PO. Reduction of lipid peroxidation with intra-operative superoxide dismutase treatment decreases intimal hyperplasia in experimental vein grafts. J Surg Res 1999;84:223-32. (Pubitemid 29390002)
42. Muzaffar S, Shukla N, Jeremy JY. NADPH oxidase: a promiscuous therapeutic target for cardiovascular drugs? Trends Cardiovasc Med 2005;15:278-82.
43. Jeremy JY, Dashwood M, Mehta D, Izzat MB, Bryan AJ, Angelini GD. Nitric oxide synthase, prostacyclin and cyclic nucleotides in externally stented porcine vein grafts. Atherosclerosis 1998;141:297-305. (Pubitemid 28539637)
44. Jeremy JY, Dashwood M, Timm M, Izzat M, Angelini G. Nitric oxide synthase and cyclic nucleotide synthesis by porcine venous-arterial grafts. Ann Thorac Surg 1997;63:470-6. (Pubitemid 27084575)
45. Wan S, Yim A, Shukla N, Johnson JL, Angelini GD, Jeremy JY. Nitric oxide donating aspirin (NCX 4016) inhibits neointimal thickening in a pig model of saphenous vein into carotid artery interposition grafting: a comparison with aspirin and morpholinosydnonimine. J Thorac Cardiovasc Surg 2007;133:494-500.
46. Muzaffar S, Jeremy JY, Angelini GD, Shukla N. The role of the endothelium and nitric oxide synthases in modulating superoxide formation induced by endotoxin and cytokines in porcine pulmonary arteries. Thorax 2003;58:598-604. (Pubitemid 36808131)
47. Muzaffar S, Shukla N, Bond M, Sala Newby G, Newby AC, Angelini GD, et al. Acute inhibition of superoxide formation and rac-1 activation in human vascular smooth muscle cells by NONOate and iloprost. Prostaglandins Leukot Essent Fatty Acids 2008;78:247-55.
48. Muzaffar S, Shukla N, Angelini GD, Jeremy JY. Nitroaspirins and SIN-1, but not aspirin, inhibit the expression of endotoxin- and cytokine-induced NAPDH oxidase in vascular smooth muscle cells from pig pulmonary arteries. Circulation 2004;110:1140-7. (Pubitemid 39319015)
49. phox and endothelial nitric oxide synthase in the pulmonary artery. Thorax 2005;60:305-13.
50. Jeremy JY, Angelini GD, Khan M, Mikhailidis DP, Morgan RJ, Thompson CS, et al. Platelets, oxidant stress and erectile dysfunction: a hypothesis. Cardiovasc Res 2000;46:50-4. (Pubitemid 30155944)
51. Jeremy JY, Mikhailidis DP, Dandona P. Excitatory receptor-linked prostanoid synthesis in mammalian smooth muscle: role of calcium, protein kinases & G proteins. Prostaglandins Leukot Essent Fatty Acids Rev 1988;34:215-28.
52. Muzaffar S, Shukla N, Bond M, Sala Newby G, Newby AC, Angelini GD, et al. Superoxide from NADPH oxidase upregulates type 5 phosphodiesterase in human vascular smooth muscle cells: inhibition with iloprost and NONOate. Br J Pharmacol 2008;155:847-56.
53. Muzaffar S, Shukla N, Angelini GD, Jeremy JY. Superoxide auto-augments superoxide formation in isolated porcine pulmonary artery endothelial cells through upregulation of NADPH oxidase expression: inhibition with iloprost. Eur J Pharmacol 2006;538:108-14.
54. phox expression in arterial endothelial cells: role of protein kinases A and G. Br J Pharmacol 2008;155:984-94.
55. 2α in cultured porcine pulmonary artery vascular smooth muscle cells. Br J Pharmacol 2004;141:488-96.
56. Jeremy JY, Birkett S, Bryan AJ, Angelini GD. Cyclic nucleotide synthesis by freshly isolated and surgically prepared human saphenous vein before and after 14 days culture. Eur J Vasc Endovasc Surg 1997;13:72-8. (Pubitemid 27182153)
57. Jeremy JY, Izzat MB, Birkett SD, Knight DM, Bryan AJ, Angelini GD. Reduced prostacyclin and increased leukotriene B4 synthesis in porcine vein grafts. Ann Thorac Surg 1996;61:143-8.
58. Plane F, Wiley KE, Jeremy JY, Cohen RA, Garland CL. Evidence that different mechanisms underlie smooth muscle relaxation to nitric oxide and nitric oxide donors in the rabbit isolated carotid artery. Br J Pharmacol 1998;123:1251-358.
59. Duerrschmidt N, Wippich N, Goettsch W, Broemme HJ, Morawietz H. Endothelin-1 induces NAD(P)H oxidase in human endothelial cells. Biochem Biophys Res Commun 2000;269:713-7. (Pubitemid 30440367)
60. Li L, Fink GD, Watts SW, Northcott CA, Galligan JJ, Pagano PJ, et al. Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension. Circulation 2003;107:1053-8. (Pubitemid 36258731)
61. Loomis ED, Sullivan JC, Osmond DA, Pollock DM, Pollock JS. Endothelin mediates superoxide production and vasoconstriction through activation of NADPH oxidase and uncoupled nitric-oxide synthase in the rat aorta. J Pharmacol Exp Ther 2005;315:1058-64. (Pubitemid 41635391)
62. Li L, Chu Y, Fink GD, Engelhardt JF, Heistad DD, Chen AF. Endothelin-1 stimulates arterial VCAM-1 expression via NADPH oxidase-derived superoxide in mineralocorticoid hypertension. Hypertension 2003;42:997-1003. (Pubitemid 37413744)
63. Romeroa M, Jiméneza R, Sáncheza M, López- Sepúlvedaa R, Zarzueloa A, Tamargoc J, et al. Vascular superoxide production by endothelin-1 requires Src non-receptor protein tyrosine kinase and MAPK activation. Atherosclerosis 2010;212:78-85.
64. Piechota A, Polañczyk A, Goraca A. Role of endothelin-1 receptor blockers on hemodynamic parameters and oxidative stress. Pharmacol Rep 2010;62:28-34.
65. Dashwood MR, Anand R, Loesch A, Souza DS. Hypothesis: a potential role for the vasa vasorum in the maintenance of vein graft patency. Angiology 2004;55:385-95. (Pubitemid 38924368)
66. Langheinrich AC, Kampschulte M, Buch T, Bohle RM. Vasa vasorum and atherosclerosis - Quid novi? Cardiovasc Res 2007;75:649-58.
67. Mulligan-Kehoe MJ. The vasa vasorum in diseased and non diseased arteries. Am J Physiol 2010;298:H295-305.
68. Jeremy JY, Dashwood MR. Microvascular repair. In: Shepro AM, editor. Encyclopaedia of the microvasculature. Elsevier Science; 2006. p. 903-11.
69. Jeremy JY, Bulbulia R, Vijayan V, Johnson JL, Gadsdon P, Angelini GD. A bioabsorbable (polyglactin) external sheath inhibits porcine saphenous vein graft thickening. J Thorac Cardiovasc Surg 2004;127:1766-72. (Pubitemid 38725459)
70. Vijayan V, Shukla N, Smith FCT, Angelini GD, Jeremy JY. Apolyglactin biodegradable external stent prevents medial and intimal thickening but promotes marked neo vasa vasorum formation in porcine saphenous vein grafts in both the short and long term. J Vasc Surg 2004;40:1011-9.
71. Mehta D, George SJ, Jeremy JY, Izzat MB, Southgate KM, Bryan AJ, et al. External stenting reduces long-term medial and neointimal thickening and platelet derived growth factor expression in a pig model of arteriovenous bypass grafting. Nat Med 1998;4:235-9. (Pubitemid 28137380)
72. Vijayan V, Smith FC, Angelini GD, Bulbulia RA, Jeremy JY. External supports and the prevention of neointima formation in vein grafts. Eur J Vasc Endovasc Surg 2002;24:13-22. (Pubitemid 41079382)
73. George SJ, Izzat MB, Gadsdon P, Yim APC, Wan S, Angelini GD, et al. The influence of external stent material on early neointimal formation and medial wall thickening in a model of saphenous vein bypass grafting. Atherosclerosis 2001;155:329-36. (Pubitemid 32209303)
74. Knowles J, Loizidou M, Taylor I. Endothelin-1 and angiogenesis in cancer. Curr Vasc Pharmacol 2005;3:309-14. (Pubitemid 41264282)
75. Davie NJ, Gerasimovskaya EV, Hofmeister SE, Richman AP, Jones PL, Reeves JT, et al. Pulmonary artery adventitial fibroblasts cooperate with vasa vasorum endothelial cells to regulate vasa vasorum neovascularisation a process mediated by hypoxia and endothelin-1. Am J Physiol 2006;168:1793-807. (Pubitemid 43825301)
76. Miller AL, Plane F, Jeremy JY, Jackson CL. Delayed recovery of relaxation to acetylcholine in mouse isolated carotid arteries ten days after endothelial denudation. J Vasc Res 2003;40:449-59. (Pubitemid 37465093)
77. Miller AL, Witchel HJ, Hancox JC, Jackson CL, Jeremy JY. Moderately elevated plasma homocysteine impairs functional endothelial recovery following denudation of mouse carotid arteries. Metabolism 2004;53:760-5. (Pubitemid 38880908)
78. García-Villalón AL, Amezquita YM, Monge L, Fernández N, Salcedo A, Diéguez G. Endothelin-1 potentiation of coronary artery contraction after ischemia-reperfusion. Vasc Pharmacol 2008;48:109-14.
79. Zaoali MA, Abdennebi HB, Padrissa-Alteǐs S, Mahfoudh-Boussaid A, Rosello-Catafau J. Pharmacological strategies against cold ischemia reperfusion injury. Expert Opin Pharmacother 2010;11:537-55.
80. Mathew V, Hasdai D, Lerman A. The role of endothelin in coronary atherosclerosis. Mayo Clin Proc 1996;7:769-77.
81. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett Jr JC. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991;325:997-1001.
82. Lerman A, Holmes Jr DR, Bell MR, Garratt KN, Nishimura RA, Burnett Jr JC. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation 1995;92:2426-31.
83. Winkles JA, Alberts GF, Brogi E, Libby P. Endothelin-1 and endothelin receptor mRNA expression in normal and atherosclerotic human arteries. Biochem Biophys Res Commun 1993;191:1081-8. (Pubitemid 23231600)
84. Xu CB, Sun Y, Edvinsson L. Cardiovascular risk factors regulate the expression of vascular endothelin receptors. Pharm Ther 2010;127:148-55.
85. Reriani M, Raichlin E, Prasad A, Mathew V, Pumper GM, Nelson RE, et al. Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis. Circulation 2010;23:958-66.
86. Dashwood MR, Tsui JC. Endothelin-1 and atherosclerosis: potential complications associated with endothelin-receptor blockade. Atherosclerosis 2002;160:297-304. (Pubitemid 34159321)
87. Raichlin E, Prasad A, Mathew V, Kent B, Holmes Jr DR, Pumper GM, et al. Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis. Hypertension 2008;52:522-8.
88. Haynes WG, Strachan FE, Webb DJ. Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation 1995;92:357-63.
89. Jeremy JY, Shukla N, Angelini GD, Wan I, Ascione R. Sustained increases in homocysteine, copper and ceruloplasmin following coronary artery bypass grafting. Ann Thorac Surg 2002;74:1553-7. (Pubitemid 35222640)
90. Berwanger CS, Jeremy JY, Stansby G. Homocysteine and vascular disease. Br J Surg 1995;82:726-31.
91. Shukla N, Greaves NS, Angelini GD, Jeremy JY. Folic acid reduces intravascular oxidative stress in diabetic rabbits. Metabolism 2008;57:774-81. (Pubitemid 351697908)
92. Shukla N, Angelini GD, Jeremy JY. Interactive effects of homocysteine and copper on angiogenesis in porcine isolated saphenous vein. Ann Thorac Surg 2007;84:43-9. (Pubitemid 46921154)
93. Shukla N, Thompson CS, Angelini GD, Mikhailidis DP, Jeremy JY. Homocysteine augments the reduction of endothelium dependent relaxation and cGMP formation in diabetic rabbits. Diabetologia 2002;45:1325-31.
94. Wan S, LeClerc P, Vincent JL. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest 1997;112:676-92. (Pubitemid 27410703)
95. Ng CS, Wan S, Yim AP, Arifi AA. Pulmonary dysfunction after cardiac surgery. Chest 2002;121:1269-77. (Pubitemid 34280453)
96. Wan S, Izzat MB, Lee TW, Wan IY, Tang NL, Yim AP. Avoiding cardiopulmonary bypass in multivessel CABG reduces cytokine response and myocardial injury. Ann Thorac Surg 1999;68:52-7.
97. Suleiman MS, Zacharowski K, Angelini GD. Inflammatory response and cardioprotection during open-heart surgery: the importance of anaesthetics. Br J Pharmacol 2008;153:21-33.
98. Ng CSH, Wan S, Arifi AA, Yim APC. Inflammatory response to pulmonary ischemia-reperfusion injury. Surg Today 2006;36:205-14. (Pubitemid 43288711)